Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Contineum Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Contineum Therapeutics, Inc.

CTNM

Contineum Therapeutics, Inc.

About Contineum Therapeutics, Inc.

Contineum Therapeutics is a biopharmaceutical company focused on developing small molecule therapies for neuroinflammatory and neuroimmune diseases. Its portfolio includes drug candidates targeting pathways involved in conditions like pulmonary fibrosis, multiple sclerosis, and chronic pain. The company emphasizes innovative, selective compounds with potential for broad applicability, leveraging internal discovery and strategic collaborations to address significant unmet medical needs in neurology and fibrosis.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Contineum Therapeutics, Inc.

1
1
Contineum Therapeutics, Inc. Contineum Therapeutics Reports $14.5 Million Net Loss in Q1 2026, Decreases Operating Expenses

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Contineum Therapeutics, Inc. Contineum Therapeutics Reports 2025 Financial Results with Increased Net Loss

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Contineum Therapeutics, Inc. Contineum Therapeutics Reports $12.8 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Contineum Therapeutics, Inc. Contineum Therapeutics Reports $16M Net Loss in Q2 2025, Driven by Increased R&D Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Contineum Therapeutics, Inc. Contineum Therapeutics Reports $15.99 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Contineum Therapeutics, Inc. Contineum Therapeutics Reports $42.26 Million Net Loss for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Contineum Therapeutics, Inc. Contineum Therapeutics Reports Improved Financial Position, Net Losses Amid Clinical Development Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments